CytoDyn Past Earnings Performance
Past criteria checks 0/6
CytoDyn's earnings have been declining at an average annual rate of -5.7%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 25.6% per year.
Key information
-5.7%
Earnings growth rate
11.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 25.6% |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How CytoDyn makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
29 Feb 24 | 0 | -53 | 11 | 5 |
30 Nov 23 | 0 | -55 | 11 | 5 |
31 Aug 23 | 0 | -73 | 13 | 4 |
31 May 23 | 0 | -87 | 17 | 3 |
28 Feb 23 | 0 | -152 | 25 | 6 |
30 Nov 22 | 0 | -180 | 32 | 8 |
31 Aug 22 | 0 | -192 | 43 | 16 |
31 May 22 | 0 | -212 | 44 | 27 |
28 Feb 22 | 0 | -195 | 43 | 32 |
30 Nov 21 | 0 | -198 | 41 | 41 |
31 Aug 21 | 0 | -193 | 32 | 50 |
31 May 21 | 0 | -178 | 34 | 53 |
28 Feb 21 | 0 | -169 | 33 | 64 |
30 Nov 20 | 0 | -160 | 31 | 67 |
31 Aug 20 | 0 | -139 | 27 | 59 |
31 May 20 | 0 | -141 | 20 | 53 |
29 Feb 20 | 0 | -82 | 17 | 42 |
30 Nov 19 | 0 | -58 | 14 | 36 |
31 Aug 19 | 0 | -58 | 13 | 40 |
31 May 19 | 0 | -56 | 12 | 42 |
28 Feb 19 | 0 | -51 | 10 | 42 |
30 Nov 18 | 0 | -56 | 9 | 45 |
31 Aug 18 | 0 | -53 | 8 | 41 |
31 May 18 | 0 | -50 | 7 | 38 |
28 Feb 18 | 0 | -47 | 7 | 35 |
30 Nov 17 | 0 | -38 | 7 | 29 |
31 Aug 17 | 0 | -32 | 7 | 25 |
31 May 17 | 0 | -26 | 7 | 20 |
28 Feb 17 | 0 | -25 | 7 | 19 |
30 Nov 16 | 0 | -22 | 8 | 15 |
31 Aug 16 | 0 | -22 | 7 | 12 |
31 May 16 | 0 | -26 | 7 | 14 |
29 Feb 16 | 0 | -33 | 6 | 18 |
30 Nov 15 | 0 | -31 | 5 | 18 |
31 Aug 15 | 0 | -31 | 5 | 18 |
31 May 15 | 0 | -25 | 4 | 15 |
28 Feb 15 | 0 | -14 | 4 | 8 |
30 Nov 14 | 0 | -15 | 4 | 7 |
31 Aug 14 | 0 | -13 | 4 | 6 |
31 May 14 | 0 | -12 | 4 | 4 |
28 Feb 14 | 0 | -12 | 4 | 3 |
30 Nov 13 | 0 | -11 | 5 | 1 |
31 Aug 13 | 0 | -9 | 5 | 1 |
Quality Earnings: CYDY is currently unprofitable.
Growing Profit Margin: CYDY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYDY is unprofitable, and losses have increased over the past 5 years at a rate of 5.7% per year.
Accelerating Growth: Unable to compare CYDY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYDY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CYDY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.